BUSINESS: Roche acquires Genentech for $46.8B


Leading biotech company Roche, parent company of Roche Molecular Diagnostics in Pleasanton, annouced yesterday that it has reached an agreement to purchase San Francisco-based Genentech for $46.8 billion.

The merger means Swiss drugmaker Roche will acquire Genentech for $95 per share.

In a statement released by Roche, the company says the merger will make Roche the seventh largest U.S. pharmaceuticals company in terms of market share. The combined company's U.S. commercial operations in pharmaceuticals will operate under the Genentech name.

Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation.

--Janet Pelletier


Sorry, but further commenting on this topic has been closed.

Couples: Philosophy of Love
By Chandrama Anderson | 0 comments | 1,356 views

Narum, Woerner win big in Pleasanton and Livermore
By Tim Hunt | 0 comments | 798 views

Remembering Gen. Pershing, 100 years later
By Jeb Bing | 0 comments | 509 views

Keeping Our Brothers, on Thanksgiving
By Tom Cushing | 7 comments | 381 views